Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians worldwide. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.

Overall MarketRank^™

0.89 out of 5 stars

1.3 Analyst's Opinion

Consensus Rating
Dechra Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of GBX 3,438.33, Dechra Pharmaceuticals has a forecasted downside of 17.0% from its current price of GBX 4,144.
Amount of Analyst Coverage
Dechra Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

2.3 Community Rank

Outperform Votes
Dechra Pharmaceuticals has received 336 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Dechra Pharmaceuticals has received 387 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Dechra Pharmaceuticals has received 53.53% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Dechra Pharmaceuticals and other stocks. Vote “Outperform” if you believe DPH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DPH will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.8 Dividend Strength

Dividend Yield
Dechra Pharmaceuticals has a dividend yield of 0.85%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Dechra Pharmaceuticals does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Dechra Pharmaceuticals is 0.83%. This payout ratio is at a healthy, sustainable level, below 75%.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Dechra Pharmaceuticals insiders have sold 4,754.15% more of their company's stock than they have bought. Specifically, they have bought £19,838.70 in company stock and sold £963,000 in company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Dechra Pharmaceuticals is 100.10, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.05.
Price to Earnings Ratio vs. Sector
The P/E ratio of Dechra Pharmaceuticals is 100.10, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 43.70.
Price to Book Value per Share Ratio
Dechra Pharmaceuticals has a P/B Ratio of 7.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Dechra Pharmaceuticals (LON:DPH) Frequently Asked Questions

Is Dechra Pharmaceuticals a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dechra Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Dechra Pharmaceuticals stock.
View analyst ratings for Dechra Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Dechra Pharmaceuticals?

Wall Street analysts have given Dechra Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Dechra Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How has Dechra Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Dechra Pharmaceuticals' stock was trading at GBX 2,472 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, DPH shares have increased by 67.6% and is now trading at GBX 4,144.
View which stocks have been most impacted by COVID-19.

How often does Dechra Pharmaceuticals pay dividends? What is the dividend yield for Dechra Pharmaceuticals?

Dechra Pharmaceuticals declared a dividend on Monday, February 22nd. Stockholders of record on Thursday, March 4th will be given a dividend of GBX 11.11 per share on Wednesday, April 7th. This represents a dividend yield of 0.32%. The ex-dividend date is Thursday, March 4th. The official announcement can be accessed at this link.
View Dechra Pharmaceuticals' dividend history.

Is Dechra Pharmaceuticals a good dividend stock?

Dechra Pharmaceuticals pays an annual dividend of GBX 0.34 per share and currently has a dividend yield of 0.85%. The dividend payout ratio of Dechra Pharmaceuticals is 0.83%. This payout ratio is at a healthy, sustainable level, below 75%.
View Dechra Pharmaceuticals' dividend history.

What price target have analysts set for DPH?

3 equities research analysts have issued 1-year price targets for Dechra Pharmaceuticals' shares. Their forecasts range from GBX 3,200 to GBX 3,600. On average, they anticipate Dechra Pharmaceuticals' share price to reach GBX 3,438.33 in the next year. This suggests that the stock has a possible downside of 17.0%.
View analysts' price targets for Dechra Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Dechra Pharmaceuticals' key executives?

Dechra Pharmaceuticals' management team includes the following people:

Mr. Ian D. Page, CEO, MD & Exec. Director (Age 60, Pay $793k)
Mr. Paul Nicholas Sandland MAAT, FCCA, CFO & Exec. Director (Age 42, Pay $375.6k)
Dr. Anthony Gerard Griffin, MD of Dechra Veterinary Products for Europe & Exec. Director (Age 58, Pay $466k)
Dr. Susan Longhofer, Chief Scientific Officer (Age 63)
Ms. Katy Clough, Group HR Director
Mr. Mike Eldred, Pres of North America (Age 51)
Ms. Melanie Hall, Company Sec.

Who are some of Dechra Pharmaceuticals' key competitors?

Some companies that are related to Dechra Pharmaceuticals include Hutchison China MediTech (HCM), Vectura Group (VEC), Beximco Pharmaceuticals (BXP), ECO Animal Health Group (EAH), Allergy Therapeutics (AGY), Futura Medical (FUM), Trilogy International Partners (TRL), Sareum Holdings plc (SAR.L) (SAR), Avivagen (VIV), N4 Pharma (N4P), Cathay International Holdings Limited (CTI.L) (CTI), Antisense Therapeutics (ANP), Bayer Aktiengesellschaft (BAYN), Mayne Pharma Group (MAYNF) and Mayne Pharma Group (MYX).
View all of DPH's competitors.

What other stocks do shareholders of Dechra Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dechra Pharmaceuticals investors own include (TTR.L) (TTR), 1428686 (SGP.L) (SGP), JD Sports Fashion (JD), Ashtead Group (AHT), Cranswick (CWK), Drax Group (DRX), RPC Group (RPC), Robert Walters (RWA), SEB (SKP) and Barratt Developments (BDEV).

What is Dechra Pharmaceuticals' stock symbol?

Dechra Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "DPH."

How do I buy shares of Dechra Pharmaceuticals?

Shares of DPH and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Dechra Pharmaceuticals' stock price today?

One share of DPH stock can currently be purchased for approximately GBX 4,144.

How much money does Dechra Pharmaceuticals make?

Dechra Pharmaceuticals has a market capitalization of £4.48 billion and generates £566.40 million in revenue each year.

How many employees does Dechra Pharmaceuticals have?

Dechra Pharmaceuticals employs 1,889 workers across the globe.

What is Dechra Pharmaceuticals' official website?

The official website for Dechra Pharmaceuticals is www.dechra.com.

Where are Dechra Pharmaceuticals' headquarters?

Dechra Pharmaceuticals is headquartered at 24 Cheshire Business Park Cheshire Avenue, NORTHWICH, CW9 7UA, United Kingdom.

How can I contact Dechra Pharmaceuticals?

Dechra Pharmaceuticals' mailing address is 24 Cheshire Business Park Cheshire Avenue, NORTHWICH, CW9 7UA, United Kingdom. The company can be reached via phone at +44-1606-814730.

This page was last updated on 5/7/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Dechra Pharmaceuticals Share Forecast, Price & News

Adding

Adding

Adding Dechra Pharmaceuticals PLC

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Headlines

About Dechra Pharmaceuticals

MarketRank™

Overall MarketRank™